vs
Side-by-side financial comparison of BJs RESTAURANTS INC (BJRI) and Bio-Techne (TECH). Click either name above to swap in a different company.
BJs RESTAURANTS INC is the larger business by last-quarter revenue ($355.4M vs $295.9M, roughly 1.2× Bio-Techne). Bio-Techne runs the higher net margin — 12.8% vs 3.6%, a 9.3% gap on every dollar of revenue. On growth, BJs RESTAURANTS INC posted the faster year-over-year revenue change (3.2% vs -6.4%). Over the past eight quarters, Bio-Techne's revenue compounded faster (4.2% CAGR vs 2.6%).
BJ's Restaurants Inc. operates a chain of casual dining restaurants across the United States. Its menu features signature deep-dish pizzas, craft beers, handcrafted cocktails, and a wide range of American comfort food. The brand primarily serves family groups, friend gatherings, and casual diners seeking affordable, high-quality meals in a relaxed, welcoming in-store environment.
Bio-Techne Corporation is an American life sciences company that develops, manufactures and sells life science reagents, instruments and services for the research, diagnostic, and bioprocessing markets.
BJRI vs TECH — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $355.4M | $295.9M |
| Net Profit | $12.6M | $38.0M |
| Gross Margin | 74.5% | 64.6% |
| Operating Margin | 3.1% | 18.4% |
| Net Margin | 3.6% | 12.8% |
| Revenue YoY | 3.2% | -6.4% |
| Net Profit YoY | -24.2% | 68.3% |
| EPS (diluted) | $0.58 | $0.24 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $355.4M | $295.9M | ||
| Q3 25 | $365.6M | — | ||
| Q2 25 | $348.0M | $317.0M | ||
| Q1 25 | — | $316.2M | ||
| Q4 24 | $325.7M | $297.0M | ||
| Q3 24 | $349.9M | $289.5M | ||
| Q2 24 | $337.3M | $306.1M | ||
| Q1 24 | — | $303.4M |
| Q4 25 | $12.6M | $38.0M | ||
| Q3 25 | $22.2M | — | ||
| Q2 25 | $13.5M | $-17.7M | ||
| Q1 25 | — | $22.6M | ||
| Q4 24 | $-2.9M | $34.9M | ||
| Q3 24 | $17.2M | $33.6M | ||
| Q2 24 | $7.7M | $40.6M | ||
| Q1 24 | — | $49.1M |
| Q4 25 | 74.5% | 64.6% | ||
| Q3 25 | 75.2% | — | ||
| Q2 25 | 75.0% | 62.7% | ||
| Q1 25 | — | 67.9% | ||
| Q4 24 | 73.4% | 65.3% | ||
| Q3 24 | 74.3% | 63.2% | ||
| Q2 24 | 74.8% | 66.4% | ||
| Q1 24 | — | 67.4% |
| Q4 25 | 3.1% | 18.4% | ||
| Q3 25 | 5.8% | — | ||
| Q2 25 | 4.3% | -7.5% | ||
| Q1 25 | — | 12.2% | ||
| Q4 24 | -0.8% | 16.0% | ||
| Q3 24 | 3.8% | 13.8% | ||
| Q2 24 | 2.4% | 15.0% | ||
| Q1 24 | — | 22.1% |
| Q4 25 | 3.6% | 12.8% | ||
| Q3 25 | 6.1% | — | ||
| Q2 25 | 3.9% | -5.6% | ||
| Q1 25 | — | 7.1% | ||
| Q4 24 | -0.9% | 11.7% | ||
| Q3 24 | 4.9% | 11.6% | ||
| Q2 24 | 2.3% | 13.3% | ||
| Q1 24 | — | 16.2% |
| Q4 25 | $0.58 | $0.24 | ||
| Q3 25 | $0.97 | — | ||
| Q2 25 | $0.58 | $-0.11 | ||
| Q1 25 | — | $0.14 | ||
| Q4 24 | $-0.13 | $0.22 | ||
| Q3 24 | $0.72 | $0.21 | ||
| Q2 24 | $0.32 | $0.26 | ||
| Q1 24 | — | $0.31 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $23.8M | $172.9M |
| Total DebtLower is stronger | — | $260.0M |
| Stockholders' EquityBook value | $366.2M | $2.0B |
| Total Assets | $1.0B | $2.5B |
| Debt / EquityLower = less leverage | — | 0.13× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $23.8M | $172.9M | ||
| Q3 25 | $26.0M | — | ||
| Q2 25 | $19.0M | $162.2M | ||
| Q1 25 | — | $140.7M | ||
| Q4 24 | $18.4M | $177.5M | ||
| Q3 24 | $16.2M | $187.5M | ||
| Q2 24 | $18.8M | $152.9M | ||
| Q1 24 | — | $145.3M |
| Q4 25 | — | $260.0M | ||
| Q3 25 | $60.5M | — | ||
| Q2 25 | $85.5M | $346.0M | ||
| Q1 25 | — | $330.0M | ||
| Q4 24 | $66.5M | $300.0M | ||
| Q3 24 | $63.5M | $300.0M | ||
| Q2 24 | $58.0M | $319.0M | ||
| Q1 24 | — | $389.0M |
| Q4 25 | $366.2M | $2.0B | ||
| Q3 25 | $386.6M | — | ||
| Q2 25 | $371.5M | $1.9B | ||
| Q1 25 | — | $2.0B | ||
| Q4 24 | $376.2M | $2.1B | ||
| Q3 24 | $386.5M | $2.1B | ||
| Q2 24 | $375.4M | $2.1B | ||
| Q1 24 | — | $2.0B |
| Q4 25 | $1.0B | $2.5B | ||
| Q3 25 | $1.0B | — | ||
| Q2 25 | $1.0B | $2.6B | ||
| Q1 25 | — | $2.6B | ||
| Q4 24 | $1.0B | $2.7B | ||
| Q3 24 | $1.0B | $2.7B | ||
| Q2 24 | $1.0B | $2.7B | ||
| Q1 24 | — | $2.7B |
| Q4 25 | — | 0.13× | ||
| Q3 25 | 0.16× | — | ||
| Q2 25 | 0.23× | 0.18× | ||
| Q1 25 | — | 0.16× | ||
| Q4 24 | 0.18× | 0.14× | ||
| Q3 24 | 0.16× | 0.14× | ||
| Q2 24 | 0.15× | 0.15× | ||
| Q1 24 | — | 0.19× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BJRI
Segment breakdown not available.
TECH
| Diagnostics And Spatial Biology | $81.2M | 27% |
| EMEA Excluding UK | $75.4M | 25% |
| Other | $42.4M | 14% |
| Instruments | $29.6M | 10% |
| APAC Excluding Greater China | $22.7M | 8% |
| Services | $22.3M | 8% |
| GB | $13.7M | 5% |
| Royalty | $8.5M | 3% |
